123 related articles for article (PubMed ID: 36762693)
1. Exploring the potential and identifying
Gurushankar K; Rimac H; Nadezhda P; Grishina M
J Biomol Struct Dyn; 2023; 41(23):13963-13976. PubMed ID: 36762693
[TBL] [Abstract][Full Text] [Related]
2. Computational assessment of
Singh A; Kumar S; Gupta VK; Singh S; Dwivedi VD; Mina U
J Biomol Struct Dyn; 2023 Jul; 41(11):4903-4916. PubMed ID: 35549811
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
[TBL] [Abstract][Full Text] [Related]
4. Phthalide derivatives as dihydrofolate reductase inhibitors for malaria: molecular docking and molecular dynamics studies.
Ibraheem W; Makki AA; Alzain AA
J Biomol Struct Dyn; 2023 Jul; 41(11):5127-5137. PubMed ID: 35635144
[No Abstract] [Full Text] [Related]
5. Homology modelling, molecular docking, and molecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A.
Vadloori B; Sharath AK; Prabhu NP; Maurya R
BMC Res Notes; 2018 Apr; 11(1):246. PubMed ID: 29661206
[TBL] [Abstract][Full Text] [Related]
6. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
Yang X; Wedajo W; Yamada Y; Dahlroth SL; Neo JJ; Dick T; Chui WK
Eur J Med Chem; 2018 Jan; 144():262-276. PubMed ID: 29274493
[TBL] [Abstract][Full Text] [Related]
7. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
[TBL] [Abstract][Full Text] [Related]
9. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
11. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
Desai NC; Trivedi AR; Khedkar VM
Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
[TBL] [Abstract][Full Text] [Related]
12. Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR.
Jayaraman P; Sakharkar KR; Lim C; Siddiqi MI; Dhillon SK; Sakharkar MK
Drug Des Devel Ther; 2013; 7():449-75. PubMed ID: 23818757
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation.
Mugumbate G; Abrahams KA; Cox JA; Papadatos G; van Westen G; Lelièvre J; Calus ST; Loman NJ; Ballell L; Barros D; Overington JP; Besra GS
PLoS One; 2015; 10(3):e0121492. PubMed ID: 25799414
[TBL] [Abstract][Full Text] [Related]
14. In silico screening of inhibitors against human dihydrofolate reductase to identify potential anticancer compounds.
Soofi A; Rezaei-Tavirani M; Safari-Alighiarloo N
J Biomol Struct Dyn; 2023; 41(23):14497-14509. PubMed ID: 36883866
[TBL] [Abstract][Full Text] [Related]
15. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Kumar M; Vijayakrishnan R; Subba Rao G
Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
[TBL] [Abstract][Full Text] [Related]
16. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Cheng YS; Sacchettini JC
Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
[TBL] [Abstract][Full Text] [Related]
17. Electronic properties investigation of human dihydrofolate reductase complexes with ligands.
Naumovich V; Grishina M; Novak J; Pathak P; Potemkin V; Shahbaaz M; Abdellattif MH
J Biomol Struct Dyn; 2022 Jul; 40(11):4775-4790. PubMed ID: 33345753
[TBL] [Abstract][Full Text] [Related]
18. Withasomniferol C, a new potential SARS-CoV-2 main protease inhibitor from the
Kandagalla S; Rimac H; Gurushankar K; Novak J; Grishina M; Potemkin V
PeerJ; 2022; 10():e13374. PubMed ID: 35673392
[TBL] [Abstract][Full Text] [Related]
19. Potency boost of a
Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
[TBL] [Abstract][Full Text] [Related]
20. Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from
Ribeiro JA; Hammer A; Libreros-Zúñiga GA; Chavez-Pacheco SM; Tyrakis P; de Oliveira GS; Kirkman T; El Bakali J; Rocco SA; Sforça ML; Parise-Filho R; Coyne AG; Blundell TL; Abell C; Dias MVB
ACS Infect Dis; 2020 Aug; 6(8):2192-2201. PubMed ID: 32603583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
